Top

Published in:

01-11-2014 | Vascular Biology (RS Rosenson, Section Editor)

8-Hydroxy-2′-Deoxyguanosine and Cardiovascular Disease: a Systematic Review

Authors: Lona J. Kroese, Peter G. Scheffer

Published in: Current Atherosclerosis Reports | Issue 11/2014

Abstract

Oxidative stress due to an excess of reactive oxygen species (ROS) may play a role in the development and progression of cardiovascular disease (CVD). 8-hydroxy-2′-deoxyguanosine (8-OHdG) is a marker of oxidative DNA damage caused by ROS. This review aimed to assess the association between 8-OHdG and CVD by reviewing the literature. Studies in human subjects using either plasma or urine to determine 8-OHdG concentrations were surveyed. Eighteen relevant studies were found, of which 13 were case-control studies and five had a prospective design. Without exception, the case-control studies showed significant positive associations between 8-OHdG and CVD. In agreement, two prospective studies showed a significant association of 8-OHdG and heart failure. Furthermore, two prospective studies found a significant association between 8-OHdG and stroke, and finally, one prospective study showed a borderline significant (p = 0.08) association between coronary artery disease (CAD) patients developing a cardiac event and 8-OHdG concentrations. In conclusion, high levels of 8-OHdG in blood and urine are associated with atherosclerosis and heart failure, but further large prospective studies are needed to investigate 8-OHdG as a predictor for cardiovascular diseases.

D’Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813–24.PubMedCrossRef

Sies H. Oxidative stress: from basic research to clinical application. Am J Med. 1991;91:31S–8.PubMedCrossRef

Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004;567:1–61.PubMedCrossRef

Cooke MS, Evans MD. 8-Oxo-deoxyguanosine: reduce, reuse, recycle? Proc Natl Acad Sci U S A. 2007;104:13535–6.PubMedCrossRefPubMedCentral

Park EM, Shigenaga MK, Degan P, et al. Assay of excised oxidative DNA lesions: isolation of 8-oxoguanine and its nucleoside derivatives from biological fluids with a monoclonal antibody column. Proc Natl Acad Sci U S A. 1992;89:3375–9.PubMedCrossRefPubMedCentral

Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.PubMedCrossRef

Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993;90:7915–22.PubMedCrossRefPubMedCentral

Fruehauf JP, Meyskens Jr FL. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007;13:789–94.PubMedCrossRef

Cadet J, Delatour T, Douki T, et al. Hydroxyl radicals and DNA base damage. Mutat Res. 1999;424:9–21.PubMedCrossRef

10.

Pryor WA. Why is the hydroxyl radical the only radical that commonly adds to DNA? Hypothesis: it has a rare combination of high electrophilicity, high thermochemical reactivity, and a mode of production that can occur near DNA. Free Radic Biol Med. 1988;4:219–23.PubMedCrossRef

11.

Collins AR, Gedik CM, Olmedilla B, et al. Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates. FASEB J. 1998;12:1397–400.PubMed

12.

Henle ES, Linn S. Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem. 1997;272:19095–8.PubMedCrossRef

13.

Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res. 1992;275:331–42.PubMedCrossRef

14.

Boveris A, Valdez LB, Zaobornyj T, et al. Mitochondrial metabolic states regulate nitric oxide and hydrogen peroxide diffusion to the cytosol. Biochim Biophys Acta. 2006;1757:535–42.PubMedCrossRef

15.

van Loon B, Markkanen E, Hubscher U. Oxygen as a friend and enemy: how to combat the mutational potential of 8-oxo-guanine. DNA Repair (Amst). 2010;9:604–16.CrossRef

16.

Yin B, Whyatt RM, Perera FP, et al. Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med. 1995;18:1023–32.PubMedCrossRef

17.

Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl). 1996;74:297–312.CrossRef

18.

Wu LL, Chiou CC, Chang PY, et al. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta. 2004;339:1–9.PubMedCrossRef

19.

Collins A, Cadet J, Epe B, et al. Problems in the measurement of 8-oxoguanine in human DNA. Report of a workshop, DNA oxidation, held in Aberdeen, UK, 19–21 January, 1997. Carcinogenesis. 1997;18:1833–6.PubMedCrossRef

20.

Matsumoto Y, Ogawa Y, Yoshida R, et al. The stability of the oxidative stress marker, urinary 8-hydroxy-2′- deoxyguanosine (8-OHdG), when stored at room temperature. J Occup Health. 2008;50:366–72.PubMedCrossRef

21.••

Barregard L, Moller P, Henriksen T, et al. Human and methodological sources of variability in the measurement of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine. Antioxid Redox Signal. 2013;18:2377–91.PubMedCrossRefPubMedCentral

22.

Lengger C, Schoch G, Topp H. A high-performance liquid chromatographic method for the determination of 8-oxo-7,8-dihydro-2′-deoxyguanosine in urine from man and rat. Anal Biochem. 2000;287:65–72.PubMedCrossRef

23.

Dizdaroglu M, Jaruga P, Birincioglu M, et al. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002;32:1102–15.PubMedCrossRef

24.

Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 1997;76:365–74.PubMed

25.

Hu CW, Wu MT, Chao MR, et al. Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom. 2004;18:505–10.PubMedCrossRef

26.

Yoshida R, Ogawa Y, Kasai H. Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine values measured by an ELISA correlated well with measurements by high-performance liquid chromatography with electrochemical detection. Cancer Epidemiol Biomarkers Prev. 2002;11:1076–81.PubMed

27.

Lai CQ, Tucker KL, Parnell LD, et al. PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases: the Boston Puerto Rican Health Study. Diabetes. 2008;57:809–16.PubMedCrossRefPubMedCentral

28.

Jaruga P, Rozalski R, Jawien A, et al. DNA damage products (5′R)- and (5′S)-8,5′-cyclo-2′-deoxyadenosines as potential biomarkers in human urine for atherosclerosis. Biochemistry. 2012;51:1822–4.PubMedCrossRef

29.

Xiang F, Shuanglun X, Jingfeng W, et al. Association of serum 8-hydroxy-2′-deoxyguanosine levels with the presence and severity of coronary artery disease. Coron Artery Dis. 2011;22:223–7.PubMedCrossRef

30.

Arao K, Yasu T, Umemoto T, et al. Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J. 2009;73:1523–30.PubMedCrossRef

31.

Arca M, Conti B, Montali A, et al. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol. 2008;28:752–7.PubMedCrossRef

32.

Himmetoglu S, Dincer Y, Bozcali E, et al. Oxidative DNA damage and antioxidant defense after reperfusion in acute myocardial infarction. J Investig Med. 2009;57:595–9.PubMed

33.

Nagayoshi Y, Kawano H, Hokamaki J, et al. Urinary 8-hydroxy-2′-deoxyguanosine levels increase after reperfusion in acute myocardial infarction and may predict subsequent cardiac events. Am J Cardiol. 2005;95:514–7.PubMedCrossRef

34.

Mizukoshi G, Katsura K, Katayama Y. Urinary 8-hydroxy-2′-deoxyguanosine and serum S100beta in acute cardioembolic stroke patients. Neurol Res. 2005;27:644–6.PubMedCrossRef

35.••

Brea D, Roquer J, Serena J, et al. Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins. BMC Neurol. 2012;12:65.PubMedCrossRefPubMedCentral

36.•

Nakajima H, Unoda K, Ito T, et al. The relation of urinary 8-OHdG, a marker of oxidative stress to DNA, and clinical outcomes for ischemic stroke. Open Neurol J. 2012;6:51–7.PubMedCrossRefPubMedCentral

37.

Nagayoshi Y, Kawano H, Hokamaki J, et al. Differences in oxidative stress markers based on the aetiology of heart failure: comparison of oxidative stress in patients with and without coronary artery disease. Free Radic Res. 2009;43:1159–66.PubMedCrossRef

38.

Watanabe E, Matsuda N, Shiga T, et al. Significance of 8-hydroxy-2′-deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J Card Fail. 2006;12:527–32.PubMedCrossRef

39.

Rivera M, Rosello-Lleti E, de Garcia BF, et al. [8-hydroxy-2′-deoxyguanosine and lipid peroxidation in patients with heart failure]. Rev Esp Cardiol. 2006;59:1140–5.CrossRef

40.

Pignatelli P, Cangemi R, Celestini A, et al. Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure. Cardiovasc Res. 2008;78:515–22.PubMedCrossRef

41.

Kono Y, Nakamura K, Kimura H, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J. 2006;70:1001–5.PubMedCrossRef

42.

Kobayashi S, Susa T, Tanaka T, et al. Urinary 8-hydroxy-2′-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail. 2011;13:29–36.PubMedCrossRef

43.••

Susa T, Kobayashi S, Tanaka T, et al. Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure. Circ J. 2012;76:117–26.PubMedCrossRef

44.••

Suzuki S, Shishido T, Ishino M, et al. 8-Hydroxy-2′-deoxyguanosine is a prognostic mediator for cardiac event. Eur J Clin Invest. 2011;41:759–66.PubMedCrossRef

45.

Wunderlich MT, Ebert AD, Kratz T, et al. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999;30:1190–5.PubMedCrossRef

46.

Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43:562–71.PubMedCrossRef

47.

White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:1044–8.PubMedCrossRefPubMedCentral

48.

Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753–66.PubMedCrossRef

49.

Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866–74.PubMedCrossRefPubMedCentral

50.

Tokunaga O, Satoh T, Yamasaki F, et al. Multinucleated variant endothelial cells (MVECs) in human aorta: chromosomal aneuploidy and elevated uptake of LDL. Semin Thromb Hemost. 1998;24:279–84.PubMedCrossRef

51.

Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992;43:219–25.PubMedCrossRef

52.

Chen KH, Srivastava DK, Singhal RK, et al. Modulation of base excision repair by low density lipoprotein, oxidized low density lipoprotein and antioxidants in mouse monocytes. Carcinogenesis. 2000;21:1017–22.PubMedCrossRef

53.

Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000;377:1–8.PubMedCrossRef

54.

Gackowski D, Kruszewski M, Jawien A, et al. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med. 2001;31:542–7.PubMedCrossRef

55.

Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med. 2003;13:270–5.PubMedCrossRef

56.

Binkova B, Smerhovsky Z, Strejc P, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res. 2002;501:115–28.PubMedCrossRef

57.

Martinet W, Knaapen MW, De Meyer GR, et al. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106:927–32.PubMedCrossRef

58.

Mahmoudi M, Mercer J, Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc Res. 2006;71:259–68.PubMedCrossRef

59.

Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006;99:156–64.PubMedCrossRef

60.

Mercer JR, Cheng KK, Figg N, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2010;107:1021–31.PubMedCrossRefPubMedCentral

61.••

Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274–83.PubMedCrossRef

62.•

Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181–90.PubMedCrossRef

63.

Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J. 2008;72(Suppl A):A31–7.PubMedCrossRef

64.

Tsutsui H, Ide T, Kinugawa S. Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal. 2006;8:1737–44.PubMedCrossRef

65.

Arbustini E, Diegoli M, Fasani R, et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol. 1998;153:1501–10.PubMedCrossRefPubMedCentral

66.

Ahuja P, Wanagat J, Wang Z, et al. Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation. 2013;127:1957–67.PubMedCrossRef

67.

Corral-Debrinski M, Shoffner JM, Lott MT, et al. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res. 1992;275:169–80.PubMedCrossRef

68.

Marin-Garcia J, Goldenthal MJ. Mitochondrial centrality in heart failure. Heart Fail Rev. 2008;13:137–50.PubMedCrossRef

69.

Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis. 2009;14:536–48.PubMedCrossRef

70.

Karamanlidis G, Nascimben L, Couper GS, et al. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res. 2010;106:1541–8.PubMedCrossRefPubMedCentral

Title: 8-Hydroxy-2′-Deoxyguanosine and Cardiovascular Disease: a Systematic Review
Authors: Lona J. Kroese
Peter G. Scheffer
Publication date: 01-11-2014
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 11/2014
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-014-0452-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

Antiplatelet Strategies for Secondary Prevention of Stroke and TIA

Disease Severity and Staging of Obesity: a Rational Approach to Patient Selection

N-3 Fatty Acids for Prevention of Cardiovascular Disease

Bariatric Surgery and Microvascular Complications of Type 2 Diabetes Mellitus

Enhancing Approaches to Therapeutic Hypothermia in Patients with Sudden Circulatory Arrest

Lipidomic Profiling at the Interface of Metabolic Surgery and Cardiovascular Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials